

AMENDMENTS TO THE CLAIMS

This Listing of Claims will replace all prior versions, including listings, of claims in the application.

Claim 1 (Canceled).

Claim 2 (Currently Amended): The compound according to claim ~~1~~ 45, wherein W is -NH-CH(E)-.

Claim 3 (Original): The compound according to claim 2, wherein -Z is a radical of the -Q-I-J-T type.

Claim 4 (Original): The compound according to claim 2, wherein -Z is a radical of the -(CH₂)_s-X-P-I-J-T type.

Claim 5 (Original): The compound according to claim 4, wherein -X- is -O-.

Claim 6 (Original): The compound according to claim 4, wherein s is 2 and -X- is -NR₄-.

Claim 7 (Currently Amended): The compound of claim ~~1~~ 45, wherein W is -N(E)-CH₂-CH₂-.

Claim 8 (Original): The compound according to claim 7, wherein -Z is a radical of the -Q-I-J-T type.

Claim 9 (Original): The compound according to claim 7, wherein -Z is a radical of the -(CH₂)_s-X-P-I-J-T type.

Claim 10 (Original): The compound according to claim 9, wherein -X- is -O-.

Claim 11 (Original): The compound according to claim 9, wherein s is 2 and -X- is -NR₄-.

Claim 12 (Currently Amended): The compound according to claim + 45, wherein -A is an -OR₁ type radical.

Claim 13 (Currently Amended): The compound according to claim + 45 selected from the group consisting of:

(2S)-3-(4-benzyloxyphenyl)-2-[4-(4-butoxybenzyloxy)benzoylamino]propionic acid methyl ester;

(2S)-3-(4-benzyloxyphenyl)-2-[4-(3-bromobenzyloxy)benzoylamino]propionic acid methyl ester;

(2S)-3-(4-benzyloxyphenyl)-2-[4-(2-chlorobenzyloxy)benzoylamino]propionic acid methyl ester;

(2S)-3-(4-benzyloxyphenyl)-2-[4-(2-fluorobenzyloxy)benzoylamino]propionic acid methyl ester;

(2S)-3-(4-benzyloxyphenyl)-2-[4-(3-methylbenzyloxy)benzoylamino]propionic acid methyl ester;

(2S)-3-(4-benzyloxyphenyl)-2-[4-(3-trifluoromethylbenzyloxy)benzoylamino]propionic acid methyl ester;

(2S)-3-(4-benzyloxyphenyl)-2-[4-(2-methoxybenzyloxy)benzoylamino]propionic acid methyl ester;

(2S)-3-(4-benzyloxyphenyl)-2-[4-(2-methylbenzyloxy)benzoylamino]propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-[4-(2-trifluoromethylbenzyloxy)benzoylamino]propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-[4-(2-*o*-tolylethoxy)benzoylamino]propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-{4-[3-(4-propoxyphenoxy)propoxy]benzoylamino}propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-[4-(3-methoxybenzyloxy)benzoylamino]propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-[4-(2-ethoxybenzyloxy)benzoylamino]propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-[4-(4-butylbenzyloxy)benzoylamino]propionic acid methyl ester;

(2*S*)-2-[4-(4-butylbenzyloxy)benzoylamino]-3-cyclohexylpropionic acid methyl ester;

(2*S*)-2-{4-[2-(3-methylquinoxalin-2-yloxy)ethoxy]benzoylamino}-3-phenylpropionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-[4-(2-pyridin-2-ylethoxy)benzoylamino]propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-{4-[2-(3-methylquinoxalin-2-yloxy)ethoxy]benzoylamino}propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-{4-[2-(pyridin-2-yloxy)ethoxy]benzoylamino}propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-{4-[2-(quinolin-8-yloxy)ethoxy]benzoylamino}propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-{4-[2-(quinolin-7-yloxy)ethoxy]benzoylamino}propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-{4-[2-(quinolin-2-yloxy)ethoxy]benzoylamino}propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-{4-[3-(3-methylquinoxalin-2-yloxy)propoxy]benzoylamino}propionic acid methyl ester;
(2*S*)-3-(4-bromophenyl)-2-{4-[2-(3-methylquinoxalin-2-yloxy)ethoxy]benzoylamino}propionic acid methyl ester;
(2*S*)-3-(4-fluorophenyl)-2-{4-[2-(3-methylquinoxalin-2-yloxy)ethoxy]benzoylamino}propionic acid methyl ester;
(2*S*)-3-(4-benzyloxyphenyl)-2-{4-[2-(3-methylquinoxalin-2-yloxy)ethoxy]benzoylamino}propionic acid ethyl ester;
(2*S*)-3-(4-benzyloxyphenyl)-2-{4-[2-(3-methylquinoxalin-2-yloxy)ethoxy]benzoylamino}propionic acid isopropyl ester;
(2*S*)-3-(4-benzyloxyphenyl)-2-{4-[2-(3-methylquinoxalin-2-yloxy)ethoxy]benzoylamino}propionic acid propyl ester;
(2*S*)-2-(4-benzyloxybenzoylamino)-3-(4-benzyloxyphenyl)propionic acid;
(2*S*)-2-[4-(3-benzyloxybenzyloxy)benzoylamino]-3-(4-benzyloxyphenyl)propionic acid;
3-{(3-benzyloxybenzyl)-[4-(2-dibenzylaminoethoxy)benzoyl]amino}propionic acid;
3-((3-benzyloxybenzyl)-{3-[2-(3-methylquinoxalin-2-yloxy)ethoxy]benzoyl}amino)propionic acid;
3-{(3-benzyloxybenzyl)-[4-(3-benzyloxybenzyloxy)benzoyl]amino}propionic acid;
2-[4-(4-benzyloxybenzyloxy)benzoylamino]-3-(4-benzyloxyphenyl)propionic acid;
(2*S*)-2-[3-(4-benzyloxybenzyloxy)benzoylamino]-3-(4-benzyloxyphenyl)propionic acid;
3-(4-benzyloxyphenyl)-2-[3-(biphenyl-4-ylmethoxy)benzoylamino]propionic acid;
2-[4-(3-benzyloxybenzyloxy)benzoylamino]-3-(4-bromophenyl)propionic acid;
3-(4-benzyloxyphenyl)-2-[4-(4-butylbenzyloxy)benzoylamino]propionic acid;
2-[4-(4-butylbenzyloxy)benzoylamino]-3-cyclohexylpropionic acid;
{(3-benzyloxybenzyl)-[4-(4-butylbenzyloxy)benzoyl]amino}acetic acid;
3-{(3-benzyloxybenzyl)-[4-(4-butylbenzyloxy)benzoyl]amino}propionic acid;
3-(4-benzyloxyphenyl)-2-[4-(2-bromobenzyloxy)benzoylamino]propionic acid;

Application Serial No. 10/560,533
Amendment and Response to Restriction
Requirement dated 24 July 2008
Reply to Office Action dated 15 May 2008

3-(4-benzyloxyphenyl)-2-[4-(2-chlorobenzyloxy)benzoylamino]propionic acid;
3-(4-benzyloxyphenyl)-2-[4-(2-methylbenzyloxy)benzoylamino]propionic acid;
3-(4-benzyloxyphenyl)-2-[4-(3-trifluoromethylbenzyloxy)benzoylamino]propionic acid;
and
3-(4-benzyloxyphenyl)-2-[4-(2-trifluoromethylbenzyloxy)benzoylamino]propionic acid.

Claim 14 (Currently Amended): A pharmaceutical composition comprising, as an active ingredient, a therapeutically effective amount of the compound according to claim ~~1~~ 45 together with appropriate amounts of pharmaceutically acceptable excipients.

Claims 15-29 (Canceled).

Claim 30 (Currently Amended): A method for the prophylactic and/or curative treatment of a condition mediated by PPAR γ in an animal including a human, comprising administering a therapeutically effective amount of a compound as defined in claim ~~1~~ 45 together with an appropriate amount of pharmaceutically acceptable excipients.

Claim 31 (Currently Amended): A method for the prophylactic and/or curative treatment of a condition mediated by both PPAR γ and PPAR δ in an animal including a human, comprising administering a therapeutically effective amount of a compound as defined in claim ~~1~~ 45 together with an appropriate amount of pharmaceutically acceptable excipients.

Claim 32 (Previously Presented): The method according to claim 30, wherein the administration is carried out orally, parenterally or topically.

Claim 33 (Currently Amended): A method for the prophylactic and/or curative treatment of an animal including a human, suffering from a condition associated with metabolic diseases,

comprising administering a therapeutically effective amount of a compound as defined in claim + 45 together with an appropriate amount of pharmaceutically acceptable excipients.

Claim 34 (Currently Amended): A method for the prophylactic and/or curative treatment of an animal including a human, suffering from a cardiovascular disease associated with metabolic syndrome, comprising administering a therapeutically effective amount of a compound as defined in claim + 45 together with an appropriate amount of pharmaceutically acceptable excipients.

Claim 35 (Currently Amended): A method for the prophylactic and/or curative treatment of an animal, including a human, suffering from inflammation or an inflammatory process in general, comprising administering a therapeutically effective amount of a compound as defined in claim + 45 together with an appropriate amount of pharmaceutically acceptable excipients.

Claim 36 (Currently Amended): A method for the prophylactic and/or curative treatment of an animal, including a human, suffering from bone diseases comprising administering a therapeutically effective amount of a compound as defined in claim + 45 together with an appropriate amount of pharmaceutically acceptable excipients.

Claim 37 (Currently Amended): A method for the prophylactic and/or curative treatment of an animal, including a human, suffering from cancer, comprising administering a therapeutically effective amount of a compound as defined in claim + 45 together with an appropriate amount of pharmaceutically acceptable excipients.

Claim 38 (Currently Amended): A method for the prophylactic and/or curative treatment of an animal, including a human, suffering from skin wound healing or cutaneous disorders associated with an anomalous differentiation of epidermic cells, particularly the formation of keloids,

comprising administering a therapeutically effective amount of a compound as defined in claim 4 together with an appropriate amount of pharmaceutically acceptable excipients.

Claim 39 (Previously Presented): The method of claim 33, wherein the metabolic disease is non-insulin-dependent diabetes mellitus (NIDDM).

Claim 40 (Previously Presented): The method of claim 33, wherein the metabolic disease is obesity.


Claim 41 (Previously Presented): The method of claim 33, wherein the metabolic disease is selected from hypercholesterolaemia and other lipid-mediated pathologies.

Claim 42 (Previously Presented): The method of claim 35, wherein the inflammatory process is selected from rheumatoid arthritis and atherosclerosis.

Claim 43 (Previously Presented): The method of claim 35, wherein the inflammatory process is selected from psoriasis and intestinal inflammatory disease.

Claim 44 (Previously Presented): The method according to claim 31, wherein the administration is carried out orally, parenterally or topically.

Claim 45 (New): A compound of formula (I),



(I)

its stereoisomers and mixtures thereof, its polymorphs and mixtures thereof, and the pharmaceutically acceptable solvates and addition salts of all of them, wherein the central benzene ring may be substituted in *meta*- or *para*- position and,

- A is a radical selected from the group consisting of -OR₁, -NR₂OR₁ and -NR₂R₃; wherein R₁, R₂ and R₃ independently represent -H or -(C₁-C₄)-alkyl;
- W- is a biradical selected from the group: -NH-CH(E)-, and -N(D)-CH₂-CH₂-; wherein E is a radical of the -G-I-J-K type and D is a radical of the -G-I'-J-K type where:
- G-- is a bond or a -(CH₂)₁₋₄- biradical;
- I- is a biradical of a cycle selected from the following groups:
- cyclohexane optionally substituted by one or several radicals independently selected from -OH, -F, -Cl, -Br, (C₁-C₄)-alkanoyl, (C₁-C₄)-alkanoyloxy, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F;
 - a five- or six-membered aromatic heterocycle containing from one to two heteroatoms selected from O, S and N, this heterocycle being optionally substituted by one or several radicals independently selected from -OH, -F,

- Cl, -Br, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F; and
- c) benzene or a bicyclic system consisting of a benzene fused with a five- or six-membered ring optionally containing from one to two heteroatoms selected from O, S and N, the benzene or the bicyclic system being optionally substituted by one or several radicals independently selected from -OH, -F, -Cl, -Br, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F;

-J- is a bond or a biradical selected from the following groups:

- a) -(CH₂)₁₋₄-alkylidene;
- b) -O- and
- c) -O-(C₁-C₄)- alkyl-;

-K is a radical selected from the following groups:

- a) -H;
- b) (C₁-C₄)-alkyl; and
- c) phenyl or phenyl optionally substituted by one or several radicals independently selected from -OH, -F, -Cl, -Br, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F;

-I'- is a biradical of a cycle selected from the following groups:

- a) benzene substituted by one or several radicals independently selected from -OH, -F, -Cl, -Br, (C₁-C₄)-alkyl optionally substituted by one or several -OH

or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F; and

- b) a bicyclic system consisting of a benzene fused with a five- or six-membered ring optionally containing from one to two heteroatoms selected from O, S and N, being this bicyclic system optionally substituted by one or several radicals independently selected from -OH, -F, -Cl, -Br, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F;

-Z is a radical selected from the following groups:

- a) -Q-I-J-T wherein

-Q- is a biradical -(CH₂)₁₋₃-;

-I- is as defined above;

-J- is as defined above; and

-T is a radical selected from the following groups:

a.a) -H;

a.b) (C₁-C₄)-alkyl;

a.c) a radical from a five- or six-membered heterocycle containing from one to two heteroatoms selected from O, S and N, this heterocycle being optionally substituted by one or several radicals independently selected from -OH, -F, -Cl, -Br, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F; and

a.d) phenyl or a bicyclic system consisting of a benzene fused with a five- or six-membered ring optionally containing from one to two heteroatoms selected from O, S and N, the phenyl or the bicyclic system being optionally substituted by one or several radicals

independently selected from -OH, -F, -Cl, -Br, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F;

b) -(CH₂)_s-X-P-I-J-T wherein

s is 2 or 3;

-X- is selected from the group consisting of -O-, -S- and -NR₄-, being R₄ a radical selected from the group:

b.a) -H;

b.b) (C₁-C₁₀)-alkyl;

b.c) phenyl, phenyl-CO-, phenyl-(C₁-C₃)-alkyl and phenyl-(C₁-C₃)-alkanoyl, being this aromatic ring optionally substituted by one or several radicals independently selected from -OH, -F, -Cl, -Br, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F; and

b.d) a heterocycle, heterocycle-CO, heterocycle-(C₁-C₃)-alkyl and heterocycle-(C₁-C₃)-alkanoyl, wherein the heterocycle is a five- or six-membered ring containing from one to two heteroatoms selected from O, S and N, being this heterocycle optionally substituted by one or several radicals independently selected from -OH, -F, -Cl, -Br, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F;

-P- is a bond or a -(CH₂)₁₋₄- biradical;

-I- is as defined above;

-J- is as defined above; and

-T is a radical as defined above;

c) -(CH₂)_u-CO-NR₅-P-I-J-T wherein

u is 1 or 2;

-R5 is a radical selected from the group:

- c.a) -H;
 - c.b) (C₁-C₁₀)-alkyl;
 - c.c) cycloalkyl and cycloalkyl-(C₁-C₃)-alkyl, wherein the cycloalkyl is a six-membered ring optionally substituted by one or several radicals independently selected from -OH, -F, -Cl, -Br, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F;
 - c.d) phenyl and phenyl-(C₁-C₃)-alkyl, being this aromatic ring optionally substituted by one or several radicals independently selected from -OH, -F, -Cl, -Br, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F; and
 - c.e) a heterocycle and heterocycle-(C₁-C₃)-alkyl, wherein the heterocycle is a five- or six-membered ring containing from one to two heteroatoms selected from O, S and N, being this heterocycle optionally substituted by one or several radicals independently selected from -OH, -F, -Cl, -Br, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F;
- P- is as defined above;
- I- is as defined above;
- J- is as defined above; and
- T is as defined above;

with the proviso that compound of formula (I) is neither of:

Application Serial No. 10/560,533
Amendment and Response to Restriction
Requirement dated 24 July 2008
Reply to Office Action dated 15 May 2008

2-(4-benzyloxybenzoylamino)-3-phenylpropionic acid,
2-[4-(4-methoxybenzyloxy)benzoylamino]-3-phenylpropionic acid,
2-[4-(4-bromobenzyloxy)benzoylamino]-3-phenylpropionic acid,
2-(4-benzyloxybenzoylamino)-3-biphenyl-4-ylpropionic acid or
2-(4-benzyloxybenzoylamino)-3-(4'-trifluoromethoxybiphenyl-4-yl)propionic acid.